

# SPECT and PET in Epilepsy and dementia and Parkinson's syndromes

John Buscombe

# Epilepsy

- Various forms of epilepsy
- In childhood and young adults can be spontaneous
- Often triggered or stopped by life events
  - Menarche
  - Pregnancy
- In older patients related to organic pathology CVA or tumour

# What is epilepsy

- It is not a fit
- Anyone if pushed enough will have a fit
  - Pyrexia
  - Metabolic
- To make a diagnosis of epilepsy need history of more than one fit
- In some a trigger identified – flashing lights
- Important diagnosis legal issues

# Types of epilepsy

- Petit mal-episodes of non-attention normally disappears by puberty
- Temporal lobe epilepsy-often suffer from deja vu or smelling an odd smell often mildy unpleasent
- Grand mal, the most common type tends to be worse in children classic fit can result in cerebral ischaemia and other injuries
- Tonic-clonic aggressive form of above may only affect one limb


# Diagnosis and treatment

- History
- Observation
- EEG for delta waves
- CT or MRI to exclude organic disease
- Treatment with anti-epileptic drugs
- Older drugs can affect cognitive function
- May not control severe fits

# Role of Nuclear Medicine

- The role is limited
- May be used to find nidus of fit
- This may be used to direct surgery
- However inter-ictal scan can be normal
- So need to inject tracer during fit
- Therefore tends to be in patients with frequent fits and in whom a trigger can be identified

# Tc-99m ECD SPECT imaging ictal showing increased perfusion of the left temporal lobe




# SPECT in epilepsy

- 1600 papers published
- Not widely used
- Most used inter-ictal and ictal imaging
- Often used subtraction imaging
- Image fusion with MRI for localisation




# Use of ictal and interictal imaging




# Subtraction imaging

- Ideal method
- Give 350MBq Tc-99m HMPAO
- Image for 30minutes
- Keep patient still
- Induce fit (normally with visual stimulus)
- During fit inject 350MBq Tc-99m HMPAO
- Image for 15 minutes
- Subtract image 1 from image 2

# Subtraction imaging



# Image fusion




# Results

- Matsuda et al Japan Ann Nuc Med 2009
  - Demonstrated that when Subtraction SPECT was used with MRI fusion 12x better localisation than not using this technique
- Goltan et al Semin Nuc Med 2008
  - Compared ictal and inter-ictal FDG PET and Tc-99m HMPAO
  - FDG response variable but Tc-99m HMPAO increase uptake at site of epilepsy in ictal scan
- Wichart-Ann Semin Nuc Med 2008
  - Used subtraction SPECT and MRI fusion of 9/17 patients with localisation of epilepsy all cured by surgery

# Why not more widely used

- Some concern on role of surgery
- New drugs based on GABA receptors better control
- Some patients resistant to idea of surgery
- Other imaging techniques such as EEG imaging

# EEG imaging



# SPECT and dementia

- Dementia
- Loss of cognitive function
- Loss of emotional stability
- Some patients additional mobility problems
- Causes
  - Alzheimer's
  - Pick's
  - Vascular
  - Lewy body
  - Parkinson plus inc MSA



# Lewy body Parkinson plus

- Identified by loss of cognitive function
- If frontal lobe syndrome and movement disorders-Lewy body
- If movement disorder then cognitive function-Parkinson's plus
- Imaging with DAT for both
- However may also need MIBG for Parkinson's plus where MSA cardiac MIBG reduced

# Diagnosis

- History
- Type of cognitive dysfunction eg behaviour or memory
- Smooth deterioration or “step wise”
- Family history (HD)
- Other risk factors
  - AI ingestion
  - Brain surgery or even brain surgeon-NvCJD

# Lab tests

- BP
- Vascular studies to carotid arteries
- Blood sugar
- TFTs
- Plasma Calcium
- CT or MRI of brain (to look for atrophy, infarcts or tumour)


# NM

- SPECT
  - I-123 IMP
  - Tc-99m HMPAO
  - Tc-99m ECD
  - (I-123 Ioflupane)
- PET
  - F-18 FDG
  - F-18 amyloid imaging
  - N-13 Ammonia


# Tc-99m HMPAO and ECD

- HMPAO
  - Advantage uptake proportional to rCBF
  - Unless stabilised must be used within 30 minutes of manufacture
  - Start SPECT at 5 mins p.i.
- ECD
  - Uptake high at low flow rates and low at high flow rates
  - Uptake in medial temporal lobe reduced
  - Start SPECT at 30 mins p.i.


# What do you see



# Early DAT




# Pick's (fronto-temporal dementia)






# DAT vs Pick's




# Patterns in AD

Parietal type




temporal type




# Mechanism of AD

- This is not clearly understood but knowledge beginning to increase
- First sign is presence of tau protein
- If tau persists then triggers laying down of beta amyloid sheets
- Beta amyloid results in neuro-fibrillary tangles-first irreversible step
- Then brain cell death

# Tau a marker of damage



# Tau imaging Tohoku, Japan



# When do we see Tau

- Tau uptake in grey matter is non-specific
- Can be related to any damage
- Seen in those post brain trauma but can clear in 12-24 months
- Seen in young schizophrenics
- Seen in early Alzheimers

# Beta amyloid imaging


- The next step is imaging beta amyloid
- However, we have beta-amyloid by 70
- So imaging restricted to those under 65 with early memory loss
- Negative study uptake in white matter, positive study uptake in grey matter of at least two lobes

# Agents used

- C-11 PiB the Pittsburgh agent not widely used because of C-11 label
- F-18 Fluorbetapir the first commercial agent made by Lilly
- F-18 Fluorbetapen which is distributed through Siemens
- Sensitivity >90%, specificity 85% determined by imaging vs PM
- If cerebral atrophy does not work




# C-11 PiB




# F-18 Flurobetapir


Note in negative study there is white matter uptake



# Vascular dementia




# Vascular dementia



# Identifying pathology directly



- Need ability to see directly at process causing DAT
- Related to deposition of neurofibrillary bundles
- These are plaques of cerebral amyloid (different from systemic amyloid)
- Coded for by the APOE-4 gene
- Imaged for the Pittsburgh agent - F-18 FDDPD

# F-18 FDDPD in memory loss





# Excluding depression




# Looking at more complex dementias

- Lewy body dementia
- Cognitive loss with rigidity
- Complex disease
- May see reduced uptake in basal ganglia
- However have reduced uptake of I-123 ioflupane like Parkinsons
- May be confused with multi-system atrophy where you get dementia + Parkinsons + Sympathetic denervation



# Imaging Parkinson's syndromes




- Different methods evolved to look at basal ganglia function
- The only licensed form is I-123  
loflupane
- Pre-synaptic uptake so not affected by most anti-Parkinson's drugs

# The Parkinson syndromes

- All involve destruction of the basal ganglia
- Parkinson's disease including that due to trauma
- Lewey body dementia
- Progressive supranuclei palsy
- Multi-system atrophy
- Last 3 sometimes called Parkinsons Plus

# Diagnosis of Parkinson's disease


- Imaging with I-123 DAT scan
- rating according to the classification reported by Catafau et al.\*



\*Catafau A.M. et al 2004, 19:1175-82. Mov. Disord.

# I-123 MIBG in MSA

- Method is to inject I-123 MIBG
- Image at 1& 4 hours
- Persistent lung uptake suggests denervation of the heart=MSA if not diabetic





# Summary

- Nuclear medicine techniques provide subtle and accurate answers to the cause of cognitive impairment maybe we do not do many tests because we do not want to know the answer?

